[Clinical microbiological investigation of vancomycin intermediate Staphylococcus aureus during glycopeptide therapy].
Kansenshogaku Zasshi
; 86(6): 734-40, 2012 Nov.
Article
em Ja
| MEDLINE
| ID: mdl-23367848
ABSTRACT
We isolated three strains of vancomycin intermediate Staphylococcus aureus (VISA) from a blood sample of a patient with infective endocarditis (VISA-1), postoperative pneumonia sputum (VISA-2), and pyogenic spondylitis blood sample (VISA-3). These VISA strains did not carry vanA, vanB, vanC1, or vanC2/C3 genes. Cell wall thickening was observed. VISA-1 and VISA-3 PFGE patterns showed the completely same pattern compared to the PFGE pattern of methicillin-resistant Staphylococcus aureus first isolated from patients 1 and 3. After 10 days on brain heart infusion agar, wall thickening in all three type of VISA was unchanged, but VISA-2 and VISA-3 reversed vancomycin susceptibility. The most suitable use of vancomycin in patients with MRSA infection thus appears to be in reducing the opportunity for cell wall thickening.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Glicopeptídeos
/
Vancomicina
/
Staphylococcus aureus Resistente à Meticilina
Idioma:
Ja
Ano de publicação:
2012
Tipo de documento:
Article